Adult stem cell therapy is a minimally-invasive option for patients with Chronic Obstructive Pulmonary Disease (COPD) including resultant emphysema and chronic bronchitis. This novel approach utilizes adult stem cells from your body fat which aim to repair the damaged tissue in your lungs while reducing inflammation and restoring the flow of oxygen-rich blood to these vital organs.

Impact On Daily Living

Because COPD prevents normal breathing, nearly every aspect of a normal life is greatly impacted as a result. Living with this condition, you may find that even seemingly simple tasks like playing with your grandchildren or carrying a load of laundry becomes increasingly challenging. This progressive disease has become the third leading cause of death in the United States according to the CDC.

What is COPD?

In the course of COPD, worsening airflow limitation makes it increasingly difficult to get air in and out through the bronchial tubes. COPD is also characterized by chronic inflammation in the lungs and system-wide inflammation throughout the body.

Symptoms of COPD can vary, but in general may include:

  • Wheezing
  • Shortness of Breath (dyspnea)
  • Fatigue
  • Frequent respiratory infections

COPD symptoms worsen over time and there is no cure known at this time.

Adult Stem Cell Therapy for COPD

Adult stem cells could be thought of as small physicians in the way that they go to work healing and repairing the body on a daily basis. It is these repair cells which take care of our bumps and bruises or normal “wear and tear.” Although your lungs possess their own population of healing adult stem cells, there are simply not enough cells present to keep up with the degree of ongoing lung tissue damage which occurs in COPD.

Surprisingly, your adipose (fat tissue) is one of the most potent and concentrated sources of adult stem cells in your body. Once isolated, these powerful healing cells can be put to work to provide cellular level repair of damage found in your lungs as a result of COPD.

Your own healing cells can target a slowed degenerative progression of COPD while restoring blood flow, addressing system-wide inflammation and repairing damaged lung tissue. The combination of these factors may lead to a number of improvements in quality of life, including:

  • Improved functional capacity
  • Better breathing
  • Increased energy and stamina
  • Reduction of bronchial infections

The Procedure

Stem cell treatment at Okyanos is a minimally invasive, same-day outpatient procedure with little recovery or down time needed.

  1. First, water-assisted fat harvesting is done to obtain about a cup and a half of adipose (fat) tissue from your abdominal area.
  2. A unique blend of stem and regenerative cells are separated from your fat tissue and prepared for injection.
  3. Immediately thereafter, your adult stem cells are delivered intravenously or by direct injection (or both) in accordance with the individualized treatment plan developed for you by the Okyanos medical team.

To learn more about Okyanos Cell Therapy for COPD, contact a Patient Liaison to request a complimentary educational consultation or dial 855-OKYANOS (855-659-2667).


Developing Cell Therapies Based on Autologous Adipose-Derived Regenerative Cells (October, 2012) in Cytori Therapeutics Fact Sheet. Retrieved from of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal Cells (March 16, 2004) in Circulation. Retrieved from:

Clinical Applications of Mesenchymal Stem Cells in Chronic Diseases (30 April 2014) in Stem Cells International. Retrieved from

An Underappreciated Source of Stem Cells for Biotechnology (April, 2006) in Trends in Biotechnology. Retrieved from

Learn COPD Basics. Retrieved February, 2015 from

Safety Study of Cell Therapy to treat Chronic Obstructive Pulmonary Disease (February, 2012.) NIH online Clinical Trials resource center. Retrieved from:

Cell Therapy For Lung Disease: A Step Forward (June, 2013) in Chest Journal. Retrieved from:

Bone Marrow–Derived Mesenchymal Stem Cells in Repair of the Injured Lung (October, 2004) in American Journal of Respiratory Cell and Molecular Biology. Retrieved from